1. Nel A, van Niekerk N, Kapiga S, Bekker LG, Gama C, Gill K, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–43.
2. Baeten JM, Palanee-Phillips T, Brown ER, Schwartz K, Soto-Torres LE, Govender V, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–31.
3. Brown ER, Hendrix CW, van der Straten A, Kiweewa FM, Mgodi NM, Palanee-Philips T, Marzinke MA, Bekker LG, Soto-Torres L, Hillier SL, Baeten JM; MTN-020/ASPIRE Study Team. Greater dapivirine
release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
J Int AIDS Soc. 2020;23(11):e25634. https://doi.org/10.1002/jia2.25634
4. Baeten TP-P J, Mgodi N, Ramjee G, Gati B, Mhlang F, Hunidzarira P, Mansoor L, Siva S, Govender V, Makanani B, Naidoo L, Singh N, Nair G, Chinula L, Mayo A, Szydlo D, Soto-Torres L, Nell A, Rosenberg Z, Hillier S, Brown E 2019 MTN-025/HOPE study team. High adherence and sustained impact on HIV-1 incidence: final results of an open-label extension trial of the dapivirine vaginal ring. IAS 2019; Mexico City, Mexico
5. Nel A 2019 Safety, adherence and HIV-1 seroconversion in DREAM-an open-label dapivirine vaginal ring trial [Abstract]. 9th SAAIDS Conference, Durban, South Africa